The NaviMed team has over 40 years of collective healthcare experience in investing, operating, and clinical activities, complementary backgrounds, past experiences working together, and a depth of high-level strategic relationships in industry and with key health policy-makers.
Mr. Schwarz has 19 years of investment and financial experience in healthcare. For fourteen years from 1997 to 2011, Mr. Schwarz led the US healthcare growth capital practice at The Carlyle Group. His team’s investing activities focused on healthcare services, digital health and medical products. He joined The Carlyle Group at the inception of its $210 million initial US venture capital fund in 1997, and led the healthcare investing practice from that time through a second fund, which closed on $602 million in 2001 targeting venture and growth capital investments, and a third fund, which closed on $605 million in 2006 targeting growth capital investments and growth-oriented leveraged buyouts.
Mr. Schwarz previously was a Vice President in the healthcare group at Robertson Stephens, where he led the firm’s digital health investment banking efforts and also served clients in the healthcare services sector. Earlier in his career, Mr. Schwarz was an investment banker at Morgan Stanley.
Mr. Schwarz is currently the Chairman of the Board of Directors of Lucent Health Solutions. He also serves as a member of the Board of Directors of AcuFocus, AqueSys, and Proteus Digital Health. He was formerly a Director of numerous prior portfolio companies of The Carlyle Group, including Carefx (sold to Harris Corporation), ConnectiCare Holdings (sold to EmblemHealth), Endius (sold to Zimmer), Fairchild Imaging (sold to BAE Systems), LipoSonix (sold to Medicis Pharmaceuticals) and Heritage Health Systems (sold to Universal American Financial).
In the non-profit sector, Mr. Schwarz serves as President of the Hungarian-American Enterprise Scholarship Fund, which provides fellowships to promising young Hungarian nationals to obtain private sector professional experience in the United States, and on the Board of the George Mason Research Foundation.
Mr. Schwarz holds an AB from Duke University where he was an Angier B. Duke Scholar, an MBA from Harvard Business School, and a JD from Harvard Law School.
Bijan Salehizadeh, M.D.
Dr. Salehizadeh has 15 years of healthcare operating and investment experience. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on growth stage healthcare investments.
Prior to joining Highland Capital Partners in 2003, Dr. Salehizadeh spent several years in a variety of operational roles at Medtronic. Before Medtronic, Dr. Salehizadeh held a variety of senior management roles with HealthCentral, a private equity-backed digital health company that went public in 1999.
He currently serves on the Board of Directors of Auris Surgical and Procured Health. Dr. Salehizadeh previously served on the Board of Directors of several companies including BÂRRX (sold to Covidien), Hyperion Therapeutics (IPO, sold to Horizon plc for $1.1 billion), and Opgen (IPO). In addition, he has sourced or been actively involved in Highland Capital Partners’ investments in AVEO (IPO), Baronova, Conor Medsystems (IPO; sold to Johnson & Johnson for $1.4 billion), Entourage Medical, kyruus, and Pharmaca Integrative Pharmacy.
Dr. Salehizadeh holds an AB in Molecular Biology from Princeton University, an MD and Master’s in Science in Health Policy from Columbia University, and an MBA from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.
Mr. Canann has 18 years of operating and investing experience with healthcare companies. Prior to co-founding NaviMed Capital, he focused on growth stage healthcare investments at The Carlyle Group between 2004 and 2011.
Previously, he led the global marketing effort for the Endeavor stent program at Medtronic, the world’s largest medical technology company. As part of the company’s focus on achieving a global market leadership position in all areas of cardiovascular technology, Mr. Canann was asked to co-lead this strategically important program, including development, communications and commercialization. In this role, he successfully managed all aspects of the global launch plan across multiple geographies to achieve the company’s sales targets in this $5 billion product category.
Prior to joining Medtronic, Mr. Canann held various strategic planning and global product management positions in the critical care division of Edwards Lifesciences (formerly Baxter International), the global leader in heart valves and hemodynamic monitoring. His responsibilities focused primarily on global product management for central venous catheters, introducers and Swan-Ganz catheters. Early in his career, Mr. Canann was a CPA in the Boston office of Price Waterhouse.
Mr. Canann currently serves on the Board of Directors of Lucent Health Solutions and previously served on the Board of Directors of several portfolio companies of The Carlyle Group including Carefx (sold to Harris Corporation), Elenza and Primary Health (sold to PacificSource Health Plans). In addition, he has been actively involved in a number of Carlyle’s other successful healthcare investments including Endius (sold to Zimmer) and AqueSys.
Mr. Canann served from 2008 to 2013 on the Cleveland Clinic Innovation Advisory Board, a select group of healthcare investors and seasoned entrepreneurs who advise the Cleveland Clinic on the commercial viability, investment decisions and funding strategies for new technologies and services and provide feedback on business plans.
Mr. Canann holds an MS and a BS from Brigham Young University and an MBA from Harvard Business School.
Mr. Chan has 7 years of healthcare experience. Prior to joining NaviMed Capital, Mr. Chan was part of the healthcare investment team at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced commercial healthcare deals worldwide, performed research on various market sectors and supported portfolio companies.
Mr. Chan also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Mr. Chan started his career developing and commercializing a molecular diagnostic product at a venture backed company.
While at Siemens, Mr. Chan was a Board Observer at MD Datacor (sold to Noridian Mutual Insurance) and actively involved in the following investments: China Diagnostics, BioImagene (sold to Roche), RadPharm (sold to JLL Partners), U-Systems (sold to GE) and Cylex (assets sold to Viracor-IBT).
Mr. Chan holds a BS in Biomedical Engineering from Johns Hopkins University and an MBA from the Wharton School at the University of Pennsylvania.
Board of Senior Advisors
Robert F. Higgins – Chairman
Mr. Higgins is a founding General Partner at Highland Capital Partners and has more than twenty-five years of experience in venture capital, having helped Highland raise nearly $3.5 billion since 1988. He has served as a director of many public and private companies. He is a former director of the National Venture Capital Association and President of the New England Venture Capital Association. In addition, Mr. Higgins has been recognized by the prestigious Forbes Midas List and AlwaysOn Venture Capital 100 as one of the top venture capitalists in the industry. In 2011, he was named a member of the American Academy of Arts and Sciences.
Mr. Higgins has been a faculty member at the Harvard Business School since 2001 and teaches at the Kennedy School of Government. He received the 2008 HBS Healthcare Alumni Achievement Award. Prior to entering venture capital, he spent four years as the Executive Director of the John A. Hartford Foundation. He also was the Chief Executive of the Clark Foundation and the Burden Foundation.
Mr. Higgins is a former Assistant to the US Secretary of Commerce and an Assistant to the head of the international division of the US Treasury. Additionally, he is a Member of the Council on Foreign Relations and a member of the Massachusetts General Hospital Research Advisory Council. He has an A.B. from Harvard College and an M.B.A. from Harvard Business School.